Diabetes News and Research

Latest Diabetes News and Research

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

New mathematical model for rapid and accurate diagnoses of AHF

Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment.

19 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

DFG Research Centre to be funded for a further four-year period

The DFG Research Centre for Renewable Therapies at the Technical University of Dresden ("Renewable Therapies: From Cells to Tissues to Therapies - Engineering the Cellular Basis of Regeneration ", CRTD), following a very successful first funding period, is being extended and will be funded for a further four years.

19 Oct 2009

Wellness provisions advance in reform legislation

Employers could incentivize wellness if provisions passed by the Senate finance and health committees become law. The Washington Post reports: "By more than doubling the maximum penalties that companies can apply to employees who flunk medical evaluations, the legislation could put workers under intense financial pressure to lose weight, stop smoking or even lower their cholesterol."

19 Oct 2009

Gloomy health care statistics in Texas top state news

New outlets report on a variety of health issues at the state level including gloomy health statistics and the rising cost of premiums for sick workers in Texas, a Medicaid program that could provide a model for national health care reform in North Carolina and Medicaid cuts in Michigan.

19 Oct 2009

Innovative tool for providing patient-centered care for diabetics

Mayo Clinic clinicians and designers, along with colleagues from other institutions, have developed and tested a tool to involve patients more in their diabetes treatment and medication choices.

19 Oct 2009

Study reveals the cost effectiveness of Rheos blood pressure lowering device

A study conducted by the University of Rochester Medical Center demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.

19 Oct 2009

Qforma introduces new phase of its healthcare database

Patients diagnosed with breast cancer or depression who are seeking a medical expert in their own community to guide them through treatment now have a place to start. Qforma, an advanced analytics and predictive modeling company, today introduced the new phase of its first-of-its-kind healthcare database "Most Influential Doctors," or MID, presented by USA TODAY.

19 Oct 2009

NFL, NDC launch 'Fuel Up to Play 60' to tackle childhood obesity

The NFL and National Dairy Council (NDC) today launch Fuel Up to Play 60, a new initiative aimed at tackling childhood obesity by giving youth a voice in changing the school nutrition and physical activity environment. The program will reach 36 million youth in 60,000 elementary, middle and high schools during the 2009/2010 school year.

15 Oct 2009

NBC Universal's 'Healthy At NBCU' to connect its health and wellness content with consumers

NBC Universal will unveil a new company-wide initiative today, "Healthy At NBCU," aimed at connecting consumers, employees and marketers with its breadth of health and wellness content. The announcement was made by Lauren Zalaznick, President NBC Universal Women and Lifestyle Entertainment Networks, who is spearheading the initiative.

15 Oct 2009

IMS Health introduces IMS MIDAS Global Biologics

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the launch of IMS MIDAS Global Biologics™, a powerful offering that enables the company’s clients to make more confident decisions as they assess opportunities in the fast-growing, $120 billion worldwide biologics market.

15 Oct 2009

Scientists are trying to decipher the chemistry of human odor

Each of the 6.7 billion people on Earth has a signature body odor - the chemical counterpart to fingerprints - and scientists are tracking down those odiferous arches, loops, and whorls in the "human odorprint" for purposes ranging from disease diagnosis to crime prevention. That's the topic of an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

15 Oct 2009

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009